FDA grants Orphan Drug Status for to-BBB’s lead product

25-Aug-2010 - Netherlands

to-BBB announced that the food and Drug Administration (FDA) has granted Orphan Drug Designation for to-BBB’s brain cancer lead product 2B3-101.

As a proprietary brain-targeted version of the marketed product Caelyx®/Doxil® (PEG-liposomal doxorubicin), 2B3-101 uses glutathione (GSH) to safely enhance the delivery of doxorubicin across the blood-brain barrier. The therapeutic benefit and predictable safety profile of 2B3-101 has been successfully demonstrated in pre-clinical studies and the product is ready to start clinical testing in a phase I/II study. 2B3-101 can be developed for multiple brain cancer indications and to-BBB considers development for brain metastases of breast cancer as well as glioma.

Other news from the department research and development

Most read news

More news from our other portals

Fighting cancer: latest developments and advances